App-Quantinova.ai

A Rise in Systolic Pulmonary Arterial Pressure at Low Level of Exercise Predicts Prognosis in Asymptomatic Patients With Organic Mitral Regurgitation -Results From the PROGRAM Study

Haifa Mahjoub - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

N/A

Impact of an Invasive Strategy on In-Hospital Outcomes in Nonagenarians With Acute Coronary Syndrome: Insights From the AMI-OPTIMA Study

Paul Farand - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Acute Coronary Syndromes

N/A

CT Derived Atherosclerotic Plaque Burden and Morphology Are Associated With Impaired Myocardial Blood Flow Using [15O]H2O PET and Fractional Flow Reserve, Independent of Luminal Obstruction

Wynand J Stuijfzand - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

Lipoprotein(a) is Not Associated With the Risk of Ischemic Cardiovascular Events Following Acute Coronary Syndrome

Christie M Ballantyne - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Acute Coronary Syndromes

Dalcetrapib

Co-aligned and Inherently Co-registered Intravascular Ultrasound and Optical Coherence Tomography in a Hybrid Imaging Catheter is Feasible for Characterizing Coronary Artery Disease

Mark Harduar - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

Compared to C-Reactive Protein and Homocysteine, [18F]-FDG PET/CTA Uptake is Directly Related to Intraplaque Inflammatory Burden of High-Risk Carotid Plaque: A Sub-Study of the Canadian Atherosclerosis Imaging Network (CAIN-2)

J. David Spence - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

HDAC6 Inhibition Potential in Pulmonary Arterial Hypertension

Olivier Boucherat - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pulmonary arterial hypertension

Monocrotaline

A Novel Mutation in Hif1? in Sprague Dawley Rats is Associated With Hyper-Responsiveness to Su5416 and Severe Pulmonary Arterial Hypertension

Yupu Deng - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

SU5416

Improved Treatment Satisfaction Independent of Stroke and Bleeding Risk Among Patients Transitioned From a Vitamin K Antagonist to Rivaroxaban: A XANTUS-ACTS Analysis

Sylvia Haas - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Non-valvular atrial fibrillation

rivaroxaban

PBI-4050 Therapy Selectively Improves Pulmonary Hypertension, Lung Remodeling and Right Ventricular Function in Heart Failure With Reduced Ejection Fraction

Martin Sirois - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart failure with reduced ejection fraction

PBI4050

The Role of Telehomecare in Blood Pressure Monitoring for Heart Failure Patients

Lusine Abrahamyan - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Risk of Myocardial Infarction Among Women versus Men With Nonobstructive Left Main Coronary Artery Disease

Tina Varghese - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Left main disease

N/A

Reduced Risk of Hyperkalemia in Heart Failure Patients Treated With an MRA and Sacubitril/Valsartan Compared With Enalapril: The PARADIGM-HF Trial

Milton Packer - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Heart failure with reduced ejection fraction

Sacubitril/valsartan

Risk of Ischemic Stroke in Newly Diagnosed Heart Failure Patients

Eric Peterson - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Arrhythmia

N/A

Assessment of Coronary Artery Disease Severity by Coronary Computed Tomography Angiography for Reclassifying Statin Eligibility Based on 2013 American College of Cardiology/American Heart Association Guidelines in Asymptomatic Individual

Briain o Hartaigh - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

Impact of Spironolactone on Profibrotic Markers in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial (TOPCAT)

Simon de Denus - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart failure with preserved ejection fraction

Spironolactone

Right Heart Load Adaptability is Predictive of Outcomes in Patients With Pulmonary Arterial Hypertension

David Boulate - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

N/A

Decreased Vascular Nitric Oxide Production Due to S100A1 Deficiency Preserves Cardiovascular Function and Survival in a Murine Model of Polymycrobial Sepsis

Jean-Francois Desjardins - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Myocardial Dysfunction

Nitric oxide

Death Despite Enalapril Therapy vs. Survival Despite Placebo in the Studies of Left Ventricular Dysfunction (SOLVD) Trial: Insights into the Role of Traditional Risk Factors for Mortality in Heart Failure and Reduced Ejection Fraction (HFrEF)

Daniel J Dooley - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart failure with reduced ejection fraction

Enalapril maleate

Clinical Effectiveness of Digoxin in Hospitalized Older Patients With Heart Failure and Preserved Ejection Fraction: A Propensity-Matched Study of Medicare-Linked OPTIMIZE-HF

Apostolos Tsimploulis - American Heart Association (AHA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

Digoxin

Filters

28841 Abstracts